Health Care & Life Sciences » Biotechnology | Nexus Biopharma Inc.

Nexus Biopharma Inc. | Balance Sheet

Fiscal year is March-February. All values USD Thousands.
2012
2013
2014
2016
2017
Cash & Short Term Investments
0.40
-
-
-
0.10
Other Current Assets
-
-
5.00
-
1.00
Total Current Assets
0.40
-
5.00
-
1.10
Net Property, Plant & Equipment
-
-
-
-
1.60
Intangible Assets
-
-
-
-
6.90
Total Assets
0.40
-
5.00
-
9.50
ST Debt & Current Portion LT Debt
-
-
-
292.50
Accounts Payable
10.10
21.50
16.20
697.80
Other Current Liabilities
17.20
20.70
32.30
425.20
Total Current Liabilities
27.30
42.20
48.60
1,415.60
Long-Term Debt
-
-
-
47.80
Total Liabilities
27.30
42.20
48.60
1,463.30
Common Equity (Total)
26.90
42.20
43.60
1,453.80
Total Shareholders' Equity
26.90
42.20
43.60
1,453.80
Total Equity
26.90
42.20
43.60
1,453.80
Liabilities & Shareholders' Equity
0.40
-
5.00
9.50

About Nexus Biopharma

View Profile
Address
8 Hillside Avenue
Montclair New Jersey 07042
United States
Employees -
Website http://www.nexusbiopharma.com
Updated 07/08/2019
Nexus Biopharma, Inc. is a preclinical stage biotechnology company developing new therapies and intellectual property for research and development activities for treating obesity and type 2 diabetes. The company was founded on July 17, 2007 and is headquartered in Montclair, New Jersey. .